Company Name Kineta
Mailing Address 219 Terry Ave N Seattle, WA 98109 USA
Company Description Through Kineta, our pioneering team is dedicated to further study of innate immunity with an aggressive strategy to develop early stage programs for powerful new antiviral and immune modulating drugs.
Proceeds Purposes Proceeds purposes were not disclosed. 20 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.